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ORIGINAL ARTICLE
A randomized study of pomalidomide vs placebo in persons
with myeloproliferative neoplasm-associated myeloﬁbrosis and
RBC-transfusion dependence
A Tefferi1, HK Al-Ali2, G Barosi3, T Devos4, H Gisslinger5, Q Jiang6, J-J Kiladjian7, R Mesa8, F Passamonti9, V Ribrag10, G Schiller11,
AM Vannucchi12,13, D Zhou14, D Reiser15, J Zhong15 and RP Gale15,16 for the RESUME trialists17
RBC-transfusion dependence is common in persons with myeloproliferative neoplasm (MPN)-associated myeloﬁbrosis.
The objective of this study was to determine the rates of RBC-transfusion independence after therapy with pomalidomide vs
placebo in persons with MPN-associated myeloﬁbrosis and RBC-transfusion dependence. Two hundred and ﬁfty-two subjects
(intent-to-treat (ITT) population) including 229 subjects conﬁrmed by central review (modiﬁed ITT population) were randomly
assigned (2:1) to pomalidomide or placebo. Trialists and subjects were blinded to treatment allocation. Primary end point was
proportion of subjects achieving RBC-transfusion independence within 6 months. One hundred and ﬁfty-two subjects received
pomalidomide and 77 placebo. Response rates were 16% (95% conﬁdence interval (CI), 11, 23%) vs 16% (8, 26%; P= 0.87). Response
in the pomalidomide cohort was associated with ⩽ 4 U RBC/28 days (odds ratio (OR) = 3.1; 0.9, 11.1), age ⩽ 65 (OR = 2.3; 0.9, 5.5) and
type of MPN-associated myeloﬁbrosis (OR= 2.6; 0.7, 9.5). Responses in the placebo cohort were associated with ⩽ 4 U RBC/28 days
(OR = 8.6; 0.9, 82.3), white blood cell at randomization425 × 109/l (OR= 4.9; 0.8, 28.9) and interval from diagnosis to randomization
42 years (OR = 4.9; 1.1, 21.9). Pomalidomide was associated with increased rates of oedema and neutropenia but these adverse
effects were manageable. Pomalidomide and placebo had similar RBC-transfusion-independence response rates in persons with
MPN-associated RBC-transfusion dependence.
Leukemia (2017) 31, 896–902; doi:10.1038/leu.2016.300
INTRODUCTION
Myeloproliferative neoplasm (MPN)-associated myeloﬁbrosis is a
clinical entity comprised of primary myeloﬁbrosis, post-
polycythaemia myeloﬁbrosis and post-essential thrombocythae-
mia myeloﬁbrosis.1 Anaemia is common in persons with MPN-
associated myeloﬁbrosis with frequencies of 30–100% in several
large series (reviewed in references Cervantes et al.2 and
Passamonti et al.3). Anaemia and RBC-transfusion dependence
are associated with poorer survival.2–6 RBC transfusions are often
given for severe anaemia. Some persons with MPN-associated
myeloﬁbrosis also have decreased platelet levels.
There is no US Food and Drug Administration- or European
Medicines Agency-approved therapy for anaemia with or without
RBC-transfusion dependence in persons with MPN-associated
myeloﬁbrosis. Common therapies include corticosteroids, andro-
genic steroids, erythropoietin, thalidomide and lenalidomide.7–18
None is proved effective in a double-blind randomized clinical
trial. Ruxolitinib, a recently Food and Drug Administration-
approved drug for myeloﬁbrosis, typically initially worsens
anaemia (reviewed in reference Santos and Verstovsek19).
Pomalidomide is an immune-modulating drug with diverse
biological actions, including effects on inﬂammation, T-cell
function, angiogenesis, proliferation and erythropoiesis.20 The
pro-erythroid activity of pomalidomide is substantially greater
than that of thalidomide or lenalidomide, and it is associated with
less bone marrow suppression especially at low doses.21,22
A phase 2 randomized Bayesian pick-the-winner study in
persons with MPN-associated myeloﬁbrosis and anaemia with or
without RBC-transfusion dependence (deﬁned using International
Working Group for Myeloﬁbrosis Research and Therapy (IWG-MRT)
criteria) compared pomalidomide, 0.5 mg/day, combined with a 3-
month course of prednisone, and pomalidomide, 2 mg/day, with
and without prednisone against prednisone only. Response rates
were similar but response duration was signiﬁcantly longer with
pomalidomide, 0.5 mg/day, and persisted after prednisone was
discontinued. This cohort was declared the winner.23 A subse-
quent phase 1/2 study showed a similar response rate to
pomalidomide without prednisone and no evidence of a higher
response rate at higher pomalidomide doses.24 Moreover, subjects
not responding to doses of pomalidomide42 mg/day had a high
response rate to pomalidomide, 0.5 mg/day. Another phase 2
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study of pomalidomide, 0.5 mg/day, without prednisone reported
a 24% response rate in subjects with anaemia with or without
RBC-transfusion dependence with JAK2V617F but no responders in
subjects without JAK2V617F.25 There was also a correlation between
anaemia response and pomalidomide-induced basophilia and a
high platelet response rate. Based on these data, a dose of
pomalidomide, 0.5 mg/day, without prednisone was selected for
further study.
We sought to determine whether therapy of persons with MPN-
associated myeloﬁbrosis and RBC-transfusion dependence with
pomalidomide, 0.5 mg/day, could increase the proportion of
persons achieving RBC-transfusion independence compared with
placebo in a randomized, double-blind parallel-group study.
Because RBC-transfusion dependence and independence are not
uniformly deﬁned, we ﬁrst conducted a RAND-Delphi consensus
panel study to develop deﬁnitions.26,27 A third response category
of clinical beneﬁt (a 50% decrease in RBC-transfusion intensity)
was also deﬁned by this process.
MATERIALS AND METHODS
Study design and objectives
This is a phase 3, multicentre, randomized, double-blind, parallel-group,
placebo-controlled study with a 2:1 allocation to pomalidomide vs
placebo. The hypothesis tested was whether data from this study are
consistent with a model where therapy with pomalidomide results in a
30% RBC-transfusion-independence response rate compared with a 10%
background rate with placebo (see ‘Sample size and power considerations’
below).
Subjects
Subjects with MPN-associated myeloﬁbrosis, including primary myeloﬁ-
brosis, post-polycythaemia vera myeloﬁbrosis and post-essential thrombo-
cythaemia myeloﬁbrosis ⩾ 18 years of age, were eligible. Bone marrow
samples were collected and reviewed postrandomization by a blinded
central observer (James Vardiman; University of Chicago). Subjects had to
be RBC-transfusion dependent deﬁned as an average RBC-transfusion
frequency ⩾ 2 U/28 days over ⩾ 84 days immediately prerandomization
with no interval 442 days without ⩾ 1 RBC transfusion. Only RBC
transfusions given for a haemoglobin concentration ⩽ 90 g/l were scored
in determining eligibility. (For countries following Nordic guidelines,
haemoglobin levels for RBC transfusions should not exceed 100 g/l
haemoglobin.) RBC transfusions given because of bleeding or chemother-
apy- or radiation-induced anaemia were also excluded. Haemoglobin
concentration at randomization had to be ⩽ 130 g/l. Subjects should not
have received thalidomide, lenalidomide, drugs which suppress bone
marrow function or any investigational drug o1 month prerandomization.
Androgenic steroids and erythropoietin were prohibited within 3 months
prerandomization and hydroxyurea should not have been given within
6 weeks prerandomization. Detailed inclusion and exclusion criteria are
presented in Supplementary Table 1. Subjects were enrolled at 72 sites,
including 18 in North America, 41 in Europe (including Russia) and 11 in
Asia. Co-investigators are listed at the end of the text before References.
Data were collected at the trial sites except for RBC transfusions given at
other sites. In this instance, detailed primary medical records were required
for review including copies of pretransfusion haemoglobin concentrations
and unit-speciﬁc records of any RBC transfusions given. Data were
independently reviewed for accuracy prerandomization by a physician
(RPG) and deputy (DR). Discordances were adjudicated or the data were
rejected and scored as a failure. Subjects carried a diary into which entries
regarding RBC transfusion had to be made by physicians at sites other than
the treating centre.
Intervention
Subjects were randomized to receive pomalidomide, 0.5 mg/day by
mouth, or matching placebo daily by mouth. Investigational product
(pomalidomide or placebo) was withheld when the haemoglobin
concentration was 4140 g/l. Subjects were evaluated for adverse events
(AEs) at each visit using the NCI CTCAE (Version 4.0) to grade severity.
Pomalidomide and placebo were interrupted or discontinued according to
prospectively deﬁned guidelines (Supplementary Table 2). There were no
dose modiﬁcations but pomalidomide or placebo could be interrupted for
up to 6 weeks for AEs. Use of drugs that might confound analyses of RBC-
transfusion dependence such as bone marrow-suppressive drugs, hydro-
xyurea, anagrelide, busulfan, immune modulators, erythropoietin, andro-
genic steroids, iron-chelating drugs and granulocyte- and granulocyte/
macrophage colony-stimulating factors were prohibited.
Outcomes
The primary end point was the proportion of subjects achieving RBC-
transfusion independence deﬁned as ⩾ 84 consecutive days with no
RBC transfusion. Secondary co-end points were time to becoming
RBC-transfusion independent, duration of RBC-transfusion independence,
survival, frequency and severity of AEs, health-care resource use and
health-related quality-of-life measures (European quality of life-5D and
Functional Assessment of Cancer Therapy-Anaemia). Exploratory end
points were prestudy subject-, disease- and therapy-related variables
correlated with RBC-transfusion independence and with response duration
and serum pomalidomide concentrations. There were unprespeciﬁed,
postunblinding analyses of the frequency of platelet response, deﬁned by
criteria of the IWG-MRT criteria15 and of clinical beneﬁt deﬁned in the
RAND-Delphi consensus panel study.26,27 This report focusses on RBC-
transfusion independence, clinical beneﬁt, platelet response and safety.
Analyses of other end points will be reported.
Sample size and power considerations
A sample size of 189 subjects (126 receiving pomalidomide and 63
receiving placebo) would have 90% power to detect the difference
between a response rate of 30% in the pomalidomide cohort and 10% in
the placebo cohort. The sample size calculation is based on two-sided
Pα=0.05 and testing the difference of proportions using un-pooled
estimate of variance. The study planned to randomize 210 subjects with
140 receiving pomalidomide and 70 receiving placebo to compensate for
subject attrition. An additional 42 subjects were randomized because of
commitments made by investigators to subjects already in screening and
without access to study results. This sample size increase was approved by
the Data Monitoring Committee (see section below) and by health
authorities and ethics committees at participating centres.
Randomization
Randomization was performed using a validated interactive voice response
system at a remote site. Investigators called to obtain a blinded therapy
assignment and were required to begin therapy within 3 days of
randomization. All randomized subjects were analyzed whether or not
they received therapy. The randomization sequence allocation was
stratiﬁed for three variables: (1) age (⩽ vs 465 years); (2) white blood
cell o or ⩾25 × 109/l; and (3) intensity of RBC-transfusion dependence
prerandomization (⩽ vs 44 U RBC/28 days averaged over the preceding
84 days). The ﬁrst subject was randomized on 8 September 2010 and the
last on 2 August 2012.
Blinding
Subjects, investigators and all trial participants were blinded to therapy
assignment. An unblinded independent Data Monitoring Committee was
impaneled to monitor safety. There were no planned interim analyses for
efﬁcacy or futility.
Statistical methods
Three populations were prospectively-deﬁned: (1) an intent-to-treat (ITT)
population including all randomized subjects (N= 252); (2) a modiﬁed ITT
population including all subjects with a conﬁrmed diagnosis of MPN-
associated myeloﬁbrosis by the blinded central reviewer, conﬁrmed RBC-
transfusion dependence by the blinded study monitor and who received
⩾1 dose of pomalidomide or placebo (N= 229); and (3) a safety population
including all randomized subjects receiving ⩾ 1 dose of investigational
product (N=250).
The primary efﬁcacy end point was proportion of subjects achieving
⩾ 84-day RBC-transfusion independence deﬁned as the absence of any
RBC transfusion during any consecutive rolling 84-day interval (that is, days
1–84, days 2–85 and so on) by 169 days postrandomization or beginning at
least 28 days before day 169. Subjects achieving ⩾ 84-day RBC-transfusion
independence were scored as responders. Subjects discontinued from
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therapy for any reason without achieving RBC-transfusion independence
are scored as non-responders. Efﬁcacy analyses were based on the
modiﬁed ITT population. Numbers and percentage of responders were
tabulated by therapy-assignment cohort. Fisher’s exact test was used to
compare pomalidomide and placebo at a two-side signiﬁcance level of
Pα=0.05.
Analyses of secondary efﬁcacy end points were also based on the
modiﬁed ITT population. Analyses of the duration of RBC-transfusion
independence included only subjects achieving RBC-transfusion indepen-
dence. The time origin was the date RBC-transfusion independence starts
which could be the date of randomization. Duration of the RBC-transfusion
independence was the time origin to the date of the next RBC transfusion,
which had to be ⩾ 84 days after the time origin. Duration of the RBC-
transfusion independence was analyzed using the Kaplan–Meier method.
Data were censored at the end of the treatment phase for subjects never
receiving another RBC transfusion after the time origin by the end of
treatment phase. Only subjects achieving RBC-transfusion independence
were included in the analysis of time to response. Days from randomiza-
tion to the date at which RBC-transfusion independence starts were
summarized using descriptive statistics (N, mean, median, s.d., minimum
and maximum). Day 1 was used in the analysis if the ﬁrst RBC-transfusion
independence began on the randomization date. Counts and percentages
were used to summarize discrete variables and descriptive statistics were
used to summarize continuous variables. Univariable analyses were used to
identify variables correlated with response. A multivariate logistic
regression model was then used to evaluate effects of potentially
signiﬁcant prognostic variables simultaneously and to identify the most
important variables associated with response.
Safety analyses included data from all subjects receiving ⩾ 1 dose of
investigational product (pomalidomide or placebo). AEs, causes of death,
vital signs, clinical laboratory measurements and concomitant drugs were
tabulated descriptively by therapy cohort. AEs were classiﬁed using the
Medical Dictionary for Drug Regulatory Activities coding system. Severity
of AEs was graded according to NCI CTCAE (Version 4.0) whenever
possible. Subjects with AEs were tabulated by system organ class,
preferred term and treatment regimen. Subjects with 41 occurrence of
the same event were counted only once under each system organ class
and preferred term. The AE summary includes numbers of AEs by NCI
CTCAE grade, suspected treatment-related events, events resulting in
withdrawal of pomalidomide or placebo, serious AEs and AEs of special
interest including new cancers. The most severe grade of each preferred
term reported for a subject was used for summaries of AEs by NCI CTCAE
grade. Clinical laboratory measurements were also graded according to
NCI CTCAE (Version 4.0). Cross tabulations were generated to summarize
frequencies of severity changes from baseline to the most abnormal
laboratory values during the study period. Analyses of all end points were
carried out when all subjects completed the blinded therapy phase of the
study, which ended 164 days after the last subject was randomized.
RESULTS
Subjects
There were 252 subjects in the IIT population (Figure 1). We could
not conﬁrm the diagnosis of MPN-associated myeloﬁbrosis at
central histological review in 6 subjects nor RBC-transfusion
dependence in 15. Two additional subjects received no therapy.
Consequently, we focussed our analysis on the 229 subjects in the
modiﬁed ITT population, including 152 in the pomalidomide
cohort and 77 in the placebo cohort.
Prerandomization variables of the modiﬁed ITT population are
summarized in Table 1. Median age was 70 years (range, 40–90
years). One hundred and seventy-two subjects (75%) had primary
myeloﬁbrosis, 25 (11%), post-polycythaemia vera myeloﬁbrosis
and 34 (14%), post-essential thrombocythaemia myeloﬁbrosis.
Median interval from diagnosis to randomization was 2 years
(range, 0–27 years). One hundred and twenty-nine subjects (56%)
received prior anaemia therapy including androgenic steroids 43
(19%), corticosteroids 67 (29%), erythropoietin 81 (35%) and other
therapies 9. One hundred and ninety-three subjects (84%) had
splenomegaly on physical examination and 7 had a splenectomy.
Median white blood cell was 6.0 × 109/l (range, 1–114× 109/l).
Median RBC-transfusion units/28 days averaged over 84 days
prerandomization was 3 (range, 2–13). There were no signiﬁcant
differences between the cohorts for any of these variables.
RBC-transfusion independence
Response rates in the modiﬁed ITT population were similar:
pomalidomide, 16% (95% conﬁdence interval (CI), 11, 23%) vs
placebo, 16% (8, 26%; P= 1.00). Median time to response for
pomalidomide was 7 weeks (range, 0–20 weeks) vs 2 weeks
(range, 0–15 weeks) for placebo (P= 0.22). Median response
durations were not analyzable (lower boundary of 95% CI
4.8 months) vs 5.5 months (P= 0.44). Among 25 responders in
the pomalidomide cohort, 12 had a response duration4186 days
compared with 1 of the 12 responders in the placebo cohort.
Response in both cohorts was more common in subjects with
low vs high U RBC/28 days prerandomization (pomalidomide
OR= 3.1 (0.9, 11.1); P= 0.09; placebo (OR = 8.6 ((0.9, 82.3);
P= 0.06). However, other variables associated with response to
pomalidomide including age (⩽65 vs465 years: OR = 2.3 (0.9, 5.5);
P= 0.07) and type of MPN-associated myeloﬁbrosis (primary
myeloﬁbrosis vs other: OR = 2.6 (0.7, 9.5); P= 0.14) differed from
those associated with response to placebo including white blood
cell (425 vs ⩽ 25 × 109/l; OR = 4.9 (0.8, 28.9); P= 0.08) and interval
from diagnosis to randomization (42 vs ⩽ 2 years; OR = 4.9;
(1.1, 21.9); P= 0.04). At one centre, 4 of the 12 subjects receiving
placebo responded vs 8 of the 65 at all other centres combined
(P= 0.03). This effect persisted in multivariable analyses
(Supplementary Tables 3–5). However, response rates to pomali-
domide and placebo remained comparable after excluding data
from this centre. We also examined rates of clinical beneﬁt (50%
decrease in RBC transfusions) in an unprespeciﬁed postunblinding
analysis. There was no signiﬁcant difference between the cohorts.
Three pomalidomide subjects scored as responders became RBC-
transfusion dependent when pomalidomide was stopped and
regained RBC-transfusion independence when pomalidomide was
re-started. No similar effect was seen in the placebo cohort. One
additional pomalidomide subject scored as a responder achieved a
haemoglobin concentration 4140 g/l. Pomalidomide was stopped
as speciﬁed in the protocol. The subject has a haemoglobin4140 g/l
with no subsequent pomalidomide therapy for 41.5 years. No
similar responses were seen in the placebo cohort. No prerandomi-
zation therapy (such as iron-chelating drugs, hydroxyurea, busulfan,
folic acid) was consistently associated with response to placebo.
Durations of RBC-transfusion dependence prerandomization were
similar between the cohorts.
Platelet response
Platelet response rates in subjects with baseline platelets
o50 × 109/l (pomalidomide, N= 54; placebo, N= 33) were sig-
niﬁcantly different between pomalidomide (22% (95% CI, 11,
35%)) and placebo (none (0, 12%); P= 0.006) and was not
signiﬁcantly correlated with RBC-transfusion-independence
response, P= 0.69).
Safety
Peripheral oedema, fatigue, pyrexia and diarrhoea were the most
commonly reported treatment-emergent AEs. Only peripheral
oedema and neutropenia were signiﬁcantly more common in the
pomalidomide cohort (Supplementary Table 6). The most
frequently reported grade ⩾ 3 treatment-emergent AEs were
neutropenia, thrombocytopenia, anaemia and pneumonia. There
was no signiﬁcant difference in incidences between the cohorts
except for neutropenia, which occurred in 14% of subjects
receiving pomalidomide and 6% of subjects receiving placebo
(P= 0.06).
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Table 1. Baseline variables
All (N= 229) Placebo (N=77) Pomalidomide (N= 152) P-value
Age (years; median (range)) 70 (40–90) 70 (44–81) 69 (40–90) 0.47
Sex (M/F) 168 52 116 0.16
Diagnosis to randomize (years; median (range)) 1.6 (0–27) 1.6 (0–14) 1.5 (0–27) 0.31
PMF 172 59 113 0.75
Post-PV-MF 25 8 17 1.00
Post-ET-MF 31 10 21 1.00
Spleen size (cm; median (range)) 12 (0–30) 11 (0–27) 12 (0–30) 0.52
Haemoglobin (mg/l; median (range)) 87 (40–117) 89 (54–117) 87 (40–110) 0.08
WBC (×10E+9/L/l; median (range)) 6.0 (0.9–114) 7.2 (1.2–114) 5.6 (0.9–67) 0.69
Platelets (×10E+9/L/l; median (range)) 147 (13–2108) 136 (13–2108) 157 (22–1523) 0.75
Splenectomy 7 1 6 0.52
RBC transfusions (/28 days; median (range)) 3 (2–13) 3 (2–10) 3 (2–15) 0.82
RBC transfusions (44 U/28 days) 66 25 41 0.44
No. of prior therapies (median (range)) 1 (1–4) 1 (1–4) 1 (1–4) 0.82
Abbreviations: F, female; M, male; PMF, primary myeloﬁbrosis; post-ET-MF, post-essential thrombocythemia myeloﬁbrosis; post-PV-MF, post-polycythaemia vera
myeloﬁbrosis; RBC, red blood cell; WBC, white blood cell.
Excluded  (N=39) 






Unable to meet study requirements 3
Other (incidence ≤ 2) 15  
4 subjects failed >1 criterion
Assessed for Eligibility  (N=291) 
Received ≥1 dose  (N=167) 
Discontinued placebo  (N=77) 







Loss of clinical benefit 7 
5Other
Randomized  (N=252) 
Allocated to pomalidomide  (N=168) 
Intent-to-Treat Population (ITT) 
Allocated to placebo  (N=84) 
Intent-to-Treat Population (ITT) 
Discontinued pomalidomide (N=149) 




Disease progression 18 
Non-compliance 1
No efficacy 60
Loss of clinical benefit 5 
Other 6 
Received at ≥1 dose  (N=83) 
Excluded from modified ITT (mITT) 
population (N=16) 
Reason for exclusion N
Not RBC-transfusion-dependent 10
Diagnosis not confirmed 5
No therapy 1
Excluded from modified ITT (mITT) 
population (N=7) 
Reason for exclusion N
Not RBC-transfusion-dependent 5
Diagnosis not confirmed 1
No therapy 1
mITT population - pomalidomide   
(N=152)
mITT population - placebo   
(N=77)
Figure 1. CONSORT ﬂow diagram.
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DISCUSSION
There were no signiﬁcant differences in the proportion of subjects
with RBC-transfusion independence, time to response or response
duration between subjects receiving pomalidomide vs subjects
receiving placebo in the modiﬁed ITT population. Although the
pomalidomide response rate was within the 95% CI estimated
from our phase 2 study23 (albeit with brief, concurrent corticos-
teroids), the response rate to placebo was higher than estimated
(albeit with a lower 95% conﬁdence boundary of 8%). This high
rate of seemingly spontaneous reversals of substantial RBC-
transfusion dependence (median 3 U RBC/month averaged over
the preceding 84 days) and brief time to response (median
2 weeks) is inconsistent with the experience of most MPN experts
and literature reviews.2–6 Consequently, we searched for con-
founding factors such as prior exposures to diverse prerandomiza-
tion and postrandomization interventions but found no consistent
associations. Detailed analyses of proper coding of the investiga-
tional product and placebo was consistent with correct drug
assignment for most subjects with correct investigational product
drug assignment in a small cohort surveyed. Finally, the signiﬁcant
difference in platelet response between the cohorts favouring
pomalidomide suggests correct coding and delivery of pomali-
domide. Based on these data, we conclude no efﬁcacy of
pomalidomide in reversing RBC-transfusion dependence in
persons with MPN-associated myeloﬁbrosis. Interestingly, others
report increased platelets in persons with MPN-associated
myeloﬁbrosis receiving pomalidomide (see accompanying article
in this issue by Schlenk et al.).28,29
One interpretation of the similar response rates to pomalido-
mide and placebo is that the pomalidomide responses are
spontaneous reversals of RBC-transfusion dependence at a similar
rate to that observed in the placebo cohort. We were therefore
surprised to ﬁnd several differences in variables associated with
response between the cohorts. For example, age o65 years was
associated with response to pomalidomide, whereas age ⩾ 65
years was associated with response to placebo. Another
unexplained observation was the loss and recovery of response
after discontinuing and restarting pomalidomide but not after
discontinuing and restarting placebo. We are interrogating gene
proﬁles in subjects in this study searching for possible associations
with response to pomalidomide and to placebo.
We selected a pomalidomide dose of 0.5 mg/day based on data
from phase 1/2 studies.23,24,30 In one study at the maximum tolerated
dose (3 mg/day for 21 of 28 days), there were no responders but
most subjects responded (cessation of RBC transfusions) when the
dose was decreased to 0.5 mg/day given continuously.24 Based on
these data, 0.5 mg/day was determined to be the effective dose. We
also chose not to give prednisone because the response rate at
0.5 mg/day without prednisone in one study was comparable or
higher than the response rate at the same dose using prednisone25
and because there was no difference in response rates at a dose of
2 mg/day with or without prednisone.23 In contrast to these reports,
preliminary data from another phase 2 study suggest a higher
response rate to 2 mg/day vs 0.5 mg/day of pomalidomide and
longer response durations with concomitant prednisone.29 Based on
these data, our conclusion of no effect of pomalidomide on RBC-
transfusion dependence is restricted to the dose and schedule we
tested and to its use without concomitant prednisone.
The IWG-MRT recently published a new guideline deﬁning RBC-
transfusion dependence and independence.31 The deﬁnition of
RBC-transfusion dependence is less stringent than we used
because we averaged transfusions over 84 days (which had to
be ⩾ 6 U RBCs) and no 42-day RBC-transfusion-free interval,
whereas they had no exclusionary RBC-transfusion-free 42-day
interval. We also excluded subjects with a haemoglobin concen-
tration 4130 g/l at randomization, whereas there was no similar
exclusion in the IWG-MRT criteria. Based on these considerations,
our eligibility criteria were more stringent than those proposed by
the IWG-MRT. Response criteria are similar, 84 days with no RBC
transfusion. However, the IWG-MRT criteria require a haemoglobin
concentration ⩾ 85 g/l (when is not speciﬁed, presumably at the
time response is declared), whereas we had no such requirement.
As a check, we re-evaluated responders in the pomalidomide and
placebo cohorts and censored subjects in whom haemoglobin
concentration at the time response was declared was o85 g/l.
Response rates were similar to those using the RAND-Delphi
criteria. We also analyzed two variables reported in a phase 2
study to correlate them with anaemia response to pomalidomide,
JAK2V617F and pomalidomide-induced basophilia.32 We could not
conﬁrm either association (data not shown) nor did our conclusion
change when we considered response rates only in subjects with
JAK2V617F.
Finally, we analyzed the validity of our conclusion regarding lack of
efﬁcacy of pomalidomide using the relevant Grading of Evidence,
Assessment, Development and Evaluation (GRADE) criteria including:
(1) overall risk of bias; (2) imprecision; (3) inconsistency (4) indirectness,
and (5) publication bias (http://gdt.guidelinedevelopment.org/central_
prod/_design/client/handbook/handbook.html). Risks of bias and im-
precision are low. However, the precisely deﬁned population of
subjects with RBC-transfusion dependence we studied is not represen-
tative of all persons with MPN-associated myeloﬁbrosis requiring
therapy for anaemia (indirectness of the study population). For
example, most persons with MPN-associated myeloﬁbrosis who are
RBC-transfusion dependent receive o2 U RBCs per 28 days over a
⩾3-month interval. Moreover, the rigid RBC-transfusion-independence
response criteria we used do not reﬂect the clinical beneﬁt physicians
expect wherein a450% reduction in RBC-transfusion intensity may be
considered beneﬁcial depending on the baseline intensity such as
the 50% reduction deﬁned as clinical beneﬁt in our RAND-Delphi study
(refer Begna et al.25; indirectness of end point). We chose our entry
and response criteria based on discussions with health authorities
regarding requirements for drug registration. Consequently, the
strength of our conclusion of no efﬁcacy should be downgraded
according to the GRADE criteria. The GRADE sphere of publication bias
is not applicable to our study as only one other randomized trial of
pomalidomide in MPN-associated myeloﬁbrosis is reported.29
Perhaps the most important conclusion from our study is the
need for a double-blind randomized control cohort when studying
interventions designed to reverse anaemia and especially RBC-
transfusion dependence in persons with MPN-associated myeloﬁ-
brosis and possibly other diseases where anaemia is an important
issue. Results of uncontrolled studies with response rate within the
8–26% 95% CI of our placebo cohort should be viewed cautiously.
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